Research
FORUM TRANSCRIPT

US CGM Market – Dexcom, Medtronic & Abbott – Medtronic's Return to Market & Updated Competitive Landscape

  • Public Equity
  • Healthcare
  • Global
PREMIUM

Specialist

Former VP at Senseonics Holdings Inc

Agenda

  • Recent trends and developments in the CGM (continuous glucose monitoring) device market and strategies to penetrate type 1 and type 2 diabetes populations
  • Competitive landscape and product differentiation – Dexcom’s (NASDAQ: DXCM) G7, Medtronic’s (NYSE: MDT) MiniMed and Abott’s (NYSE: ABT) Freestyle Libre 3, including compatibility with pumps, usability and other features to meet changing patient demands
  • Quality control outlook for Medtronic's MiniMed device and expectations for a new sensor in 2024
  • Potential threats for CGM market disruption, including emerging players and increase of weight loss drug use for the type 2 population
  • Global CGM global market opportunity and successful go-to-market dynamics

Questions

For access to this and thousands of other Transcripts, request a free trial

Request A Demo